Immunocore
IMCR
109 hedge funds and large institutions have $1.61B invested in Immunocore in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 33 reducing their positions, and 15 closing their positions.
597% more call options, than puts
Call options by funds: $22.8M | Put options by funds: $3.27M
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
12% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 33
4% more funds holding
Funds holding: 105 → 109 (+4)
1.11% more ownership
Funds ownership: 66.86% → 67.98% (+1.1%)
7% less capital invested
Capital invested by funds: $1.73B → $1.61B (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$68.7M |
| 2 |
Morgan Stanley
New York
|
+$24.8M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$24M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$15.2M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$21.6M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$18M |
| 3 |
Millennium Management
New York
|
-$12.4M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$11.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.83M |
IMCR Hedge Fund Activity: Q1 2023 in Review
109 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q1 2023, worth a combined $1.61B — down 6.6% from $1.73B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new IMCR positions and 15 closed out — a net gain of 4 holders — while 37 added to existing stakes and 33 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $68.7M. The largest seller was Avidity Partners Management, cutting an estimated $21.6M.
- 109 institutional investors held Immunocore (IMCR) as of Q1 2023, up from 105 in Q4 2022.
- Funds reported $1.61B of Immunocore stock for Q1 2023, down 6.6% quarter-over-quarter.
- 19 funds opened new Immunocore positions in Q1 2023 and 15 closed out, a net change of +4 holders.
- The largest Immunocore buyer in Q1 2023 was Wellington Management Group, an estimated $68.7M added.
- The largest Immunocore seller in Q1 2023 was Avidity Partners Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q1 2023.